Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-260-8 | CAS number: 118-56-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Dermal absorption
Administrative data
- Endpoint:
- dermal absorption in vitro / ex vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- June 14 to September 05, 2005
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: guideline test with GLP, scientific design and reporting contributed to assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 005
- Report date:
- 2005
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 428 (Skin Absorption: In Vitro Method)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
Test material
- Reference substance name:
- Homosalate
- EC Number:
- 204-260-8
- EC Name:
- Homosalate
- Cas Number:
- 118-56-9
- Molecular formula:
- C16H22O3
- IUPAC Name:
- 3,3,5-trimethylcyclohexyl salicylate
Constituent 1
- Radiolabelling:
- yes
- Remarks:
- 14-C
Test animals
- Species:
- other: in vitro in rat and human skin
- Strain:
- not specified
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- Skin membranes
Human skin was obtained from three female donors directly after abdominal surgery Donor 1 TNA17/05, 36 years of age, arrival at TNO on 28 June 2005 Donor 2 TNA18/05, 43 years of age, arrival at TNO on 1 July 2005 Donor 3 TNA 19/05, 30 years of age, arrival at TNO on 6 July 2005. Informed consent was provided by the skin donors. The transportation of the skin to the laboratory was carried out as soon as possible after dissection, while the skin was kept on ice in a plastic container. Upon arrival at the laboratory, subcutaneous fat was removed. After removal of the subcutaneous fat, the skin was dermatomed using a Dermatome 25 mm (Nouvag GmbH, Germany). Subsequently, the dermatomed skin strips were cut into smaller pieces of approximately 2 cm2. The thickness of the skin membranes was measured with a digimatic micrometer (Mitutoyo Corporation, Japan) and recorded. The mean thickness (n=6) were as follows:
Human donor 1: 0.397 ± 0.030 mm
Human donor 2:0.357 ± 0.013 mm
Human donor 3: 0.519 ±0.090 mm
Rat skin was obtained from three female rats (Sprague-Dawley, Charles River Deutschland, Sulzfeld, Germany) at ca 10-12 weeks of age After the sacrifice of the rats, the dorsal and flank skin of the animals was clipped free of fur by means of electric clippers. Skin discs with a diameter of ca 16 mm will be punched out and subcutaneous fat was carefully removed using scissors. The thickness of all skin membranes was measured with a digimatic micrometer (Mitutoyo Corporation, Japan) The mean thickness (n=6) were as follows:
Rat donor 1: 0.669± 0 047 mm
Rat donor 2: 0.755± 0 073 mm
Rat donor 3: 0.763± 0 089 mm
Flow-through diffusion cells:
The skin membranes were placed in 9 mm flow-through automated diffusion cells (PermeGear Inc,Riegelsville, PA, USA) The temperature of the skin surface was regularly checked during the course of the study and was found to be ca 32 °C, at ambient humidity. The receptor fluid was pumped at a speed of ca 1.6 mL/h. For human skin membranes, the receptor fluid consisted of a mixture of Dulbecco’s Minimum Eagle Medium (DMEM) and Ham’s FI2 culture medium (3.1) supplemented with Epidermal Growth Factor (hEGF, 10 µg/L), hydrocortisone (400 µg/L), gentamicin (50 mg/L), L-glutamine (2 mM), and Fetal Calf Serum (FCS, 10 %, v/v)
For rat skin membranes, the receptor fluid consisted of Minimal Essential Medium, supplemented with gentamicin (50 mg/L), L-glutamine (2 mM) and FCS (10 %, v/v). During the experiment, the receptor fluid was continuously gassed with ca 95% O2 and ca 5 % CO2.
Since test article is poorly soluble in water, FCS (10 %, v/v) was added to increase solubility. The actual solubility of test article in the receptor fluid was determined prior to the experiment. In addition, the solubility of test substance was tested in culture medium without FCS but containing 5 % Bovine Serum Albumin (BSA)
Receptor fluid solubility:
In order to test the solubility of test article in the receptor fluid, [14C]test article was mixed with non-radiolabeled test article. This mix was further diluted in ethanol to a concentration of 10.11 mg/mL. A volume of 45 µL (containing ca 450 µg test article) was added to a glass vial and the ethanol was evaporated under nitrogen gas. Subsequently, 5 mL receptor fluid (for human skin) containing either 10 % FCS or 5 % BSA was added (in triplicate) to a final concentration of ca 90 µg /mL. The vials were rocked on a roller platform for ca 1 h after which the vials will be left standing for ca 1h. Samples were collected from the upper, middle and lower level of each vial and analysed for the amount of radioactivity
Based on the following calculations, the required solubility of test article in the receptor fluid is ca 8 µg/mL. the maximum amount of the active ingredient applied to the skin was ca 0.5 mg/cm2 (= ca 320 µg a i /skin membrane) Assuming that 100 % of the dose reaches the receptor fluid over 24 h, the required solubility of test article is 320 µg in 38 4 mL (24 × flow rate of ca 1 6 mL/h), i e ca 8.3 µg /mL.
Based on the solubility in the receptor fluid after a 1-hour incubation period on the roller platform, receptor fluid containing 10 % FCS was selected for the absorption study. The solubility was determined to be approx. 12 µg/mL (both in receptor fluid containing 10 % FCS and 5 % BSA). After an additional 1-hour stationary incubation period, solubility was found to be lower (ca 2 – 3.5 µg/mL probably caused by precipitation of the test substance during that period Based on this test, solubility in the receptor was judged to be sufficient during the entire absorption experiment
Administration / exposure
- Type of coverage:
- other: in vitro
- Vehicle:
- not specified
- Duration of exposure:
- 24 hr
- Doses:
- 10.1%: Amount test article in formulation [%]
human skin: 544.9, 548.0, 541.2 µg/cm2
rat skin: 535.9 µg/cm2 - No. of animals per group:
- 6
- Control animals:
- no
- Remarks:
- in vitro assay
- Details on study design:
- Preparation B was made on 14 June 2005 (when the preparation of the complete formulation was tested using non-radiolabelelled homosalate). Preparation A and the complete formulation (including radiolabel) was made on 22 June 2005. The experimental phase (from date of isolation of skin membranes until recovery finishing the recovery) of this study was performed as follows: Human skin donor 1 from 28 until 29 June 2005, human skin donor 2 from 1 until 2 July 2005, human skin donor 3 from 6 until 7 July 2005. The experiments using rat skin (3 donors) were performed from 22 until 23 June 2005. Measurement radioactivity was finished by 11 July 2005.
Determination of recovery of the test substance:
Receptor fluid: The samples of the receptor fluid were collected in vials for immediate analysis by liquid scintillation counting.
Skin wash: The cotton swabs were pooled per skin membrane in glass vials and extracted using a weighed amount of ethanol for at least 24 h at room temperature.
Donor compartment: The donor compartment was washed two times with 1.0 mL ethanol.
Tape stripping: At 24 h post exposure, each skin was tape stripped using D-squame (Monaderm, Monaco) (10 times per skin membrane) Tape stripping was discontinued when the epidermis was visually damaged. The tape strip containing (pieces of) epidermis was pooled with the skin membrane.
Formulation preparation:
The complete dose formulation (that is including the radiolabel) was prepared one day prior to the start of the first experiment. All experiments were performed using the same formulation. Until use, the formulation was stored at ambient temperature and protected from light. - Details on in vitro test system (if applicable):
- Flow-through diffusion cells
The skin membranes were placed in 9 mm flow-through automated diffusion cells (PermeGear Inc., Riegelsville, PA, USA). The temperature of the skin surface was regularly checked during the course of the study and was found to be ca 32 °C at ambient humidity. The receptor fluid was pumped at a speed of ca 1.6 mL/h. For human skin membranes, the receptor fluid consisted of a mixture of Dulbecco’s Minimum Eagle Medium (DMEM) and Ham’s F12 culture medium (3 1) supplemented with Epidermal Growth Factor (hEGF, 10 µg/L), hydrocortisone (400 µg/L), gentamicin (50 mg/L), L-glutamine (2 mM), and Fetal Calf Serum (FCS, 10 %, v/v)
For rat skin membranes, the receptor fluid consisted of Minimal Essential Medium, supplemented with gentamicin (50 mg/L), L-glutamine (2 mM) and FCS (10 %, v/v). During the experiment, the receptor fluid was continuously gassed with ca 95 % O2 and ca 5 % CO2.
Since homosalate is poorly soluble in water, FCS (10 %, v/v) was added to increase solubility. The actual solubility of homosalate in the receptor fluid was determined prior to the experiment. In addition, the solubility of homosalate was tested in culture medium without FCS but containing 5 % Bovine Serum Albumin (BSA).
In order to test the solubility of homosalate in the receptor fluid, [14C]homosalate was mixed with non-radiolabeled homosalate. This mix was further diluted in ethanol to a concentration of 10 - 11 mg/mL. A volume of 45 µL (containing ca 450 µg homosalate) was added to a glass vial and the ethanol was evaporated under nitrogen gas. Subsequently, 5 mL receptor fluid (for human skin) containing either 10 % FCS or 5 % BSA was added (in triplicate) to a final concentration of ca 90 µg/mL. The vials were rocked on a roller platform for ca 1 h after which the vials will be left standing for ca 1h. Samples were collected from the upper, middle and lower level of each vial and analysed for the amount of radioactivity
Results and discussion
- Signs and symptoms of toxicity:
- not specified
- Dermal irritation:
- not specified
- Absorption in different matrices:
- In human skin, the mean flux constant for the absorption of test substance was 0.058 µg /cm2/h. The mean total absorption was 1.1 % of the applied dose and the mean recovery was 92.4%.
In rat skin, the mean flux constant for the absorption of test substance was 0.807µg/ cm2/h. The mean total absorption was 8.7 % of the applied dose and the mean recovery was 93.1%.
Details see the following tabs in the field for additional results (table 1 and table 2). - Total recovery:
- In human skin, the mean recovery was 92.4% of the applied dose.
In rat skin, the mean recovery was 93.1% of the applied dose.
Percutaneous absorptionopen allclose all
- Dose:
- 10.1%- Amount test article in formulation[%]
- Parameter:
- percentage
- Absorption:
- 1.1 %
- Remarks on result:
- other: 24 hr
- Remarks:
- human skin: 1.1% of applied dose
- Dose:
- 10.1%- Amount test article in formulation[%]
- Parameter:
- percentage
- Absorption:
- 8.7 %
- Remarks on result:
- other: 24 hr
- Remarks:
- rat skin: 8.7% of applied dose
- Conversion factor human vs. animal skin:
- Based on flux constants rat skin was ca. 14 times more permeable to test article than human skin. Based on total absorption, the difference in absorption between rat and human skin was about 8-fold.
Any other information on results incl. tables
Table 1 - Overview table of thein vitropercutaneous penetration of test article in a standard sunscreen formulation through human skin |
Group |
A |
B |
C |
|||
Amount test article in formulation[%] |
10.1 |
10.1 |
10.1 |
|||
Dose[µg/cm2] |
544.9 |
548.0 |
541.2 |
|||
n |
6 |
6 |
6 |
|||
Penetration into the receptor fluid after 24h |
µg/cm |
%of dose |
µg/cm |
%of dose |
µg/cm |
%of dose |
1.36 |
0.25 |
0.87 |
0.16 |
0.66 |
0.12 |
|
Flux constant [µg/cm2/h] |
0.077 |
0.057 |
0.039 |
|||
Lag time [h] |
6.5 |
7.0 |
7.6 |
|||
Total absorption[%of dose] |
1.4 |
0.9 |
0.9 |
Table 2 - Overview table of thein vitropercutaneous penetration of test article in a standard sunscreen formulation through rat skin |
Group |
A |
B |
C |
|||
Amount test article in formulation[%] |
10.1 |
10.1 |
10.1 |
|||
Dose[µg/cm2] |
535.9 |
535.9 |
535.9 |
|||
n |
6 |
6 |
6 |
|||
Penetration into the receptor fluid after 24h |
µg/cm |
%of dose |
µg/cm |
%of dose |
µg/cm |
%of dose |
7.12 |
1.33 |
19.37 |
3.62 |
18.50 |
3.45 |
|
Flux constant [µg/cm2/h] |
0.412 |
0.997 |
1.012 |
|||
Lag time [h] |
6.8 |
4.6 |
5.7 |
|||
Total absorption[%of dose] |
7.4 |
7.7 |
11.0 |
Applicant's summary and conclusion
- Conclusions:
- In summary, in human skin, the mean total absorption was 1.1 % of the applied dose and the mean recovery was 92.4%. In rat skin, the mean total absorption was 8.7 % of the applied dose and the mean recovery was 93.1%. Based on total absorption, the difference in absorption between rat and human skin was about 8-fold.
- Executive summary:
The study was designed to examine the in vitro percutaneous absorption of test substance through viable rat and human skin membranes using [I4C]test article.Test substance was tested in a standard sunscreen formulation at a concentration of 10.1% (w/w).The contact time was 24 hours.The objective of the study was to determine the dermal absorption of substance by monitoring the compound-related radioactivity in the receptor fluid in time. In addition to the amount of [14C]test item in the receptor fluid, the unabsorbed dose (skin wash after 24 h exposure) and the residues remaining in the skin membranes and in the stratum corneum were determined. The study was performed in flow-through diffusion cells. The study was conducted to comply with OECD 428 guideline under the GLP regulations.
The ultra violet screen was examined for its in vitro percutaneous absorption through viable human and rat skin membranes in a standard sunscreen formulation at 10.1 % (w/w). The exposure time was 24 hours. In human skin, the mean flux constant for the absorption of test substance was 0.058µg /cm2/h. The mean total absorption was 1.1 % of the applied dose and the mean recovery was 92.4%. In rat skin, the mean flux constant for the absorption oftest substance was 0.807µg/ cm2/h.The mean total absorption was 8.7 % of the applied dose and the mean recovery was 93.1%. Based on flux constants rat skin was ca 14 times more permeable to test article than human skin. Based on total absorption, the difference in absorption between rat and human skin was about 8-fold.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
